国际口腔医学杂志 ›› 2018, Vol. 45 ›› Issue (6): 716-722.doi: 10.7518/gjkq.2018.06.016

• 综述 • 上一篇    下一篇

白细胞介素-35及其与口腔疾病的关系

刘芳,蔡扬()   

  1. 贵州医科大学附属口腔医院牙周黏膜科 贵阳 550001
  • 收稿日期:2018-02-25 修回日期:2018-07-12 出版日期:2018-11-01 发布日期:2018-11-15
  • 通讯作者: 蔡扬 E-mail:caiyang85@163.com
  • 作者简介:刘芳,住院医师,硕士,Email: 1047984284@qq.com
  • 基金资助:
    国家自然科学基金(81460104)

Interleukin-35 and its relationship with oral diseases

Fang Liu,Yang Cai()   

  1. Dept. of Periodontics & Oral Medicine, Stomatological Hospital of Guizhou Medical University, Guiyang 550001, China
  • Received:2018-02-25 Revised:2018-07-12 Online:2018-11-01 Published:2018-11-15
  • Contact: Yang Cai E-mail:caiyang85@163.com
  • Supported by:
    This study was supported by the National Natural Science Foundation of China(81460104)

摘要:

白细胞介素(IL)-35是近年发现的主要由调节性T(Treg)细胞分泌的一种新型抑制性细胞因子,属于IL-12家族新成员。IL-35不仅可诱导一种新型Treg细胞或调节性B细胞的产生,而且还可抑制辅助性T(Th)17细胞和Th1细胞介导的炎性反应,从而在自身免疫性疾病、炎症性疾病及肿瘤等疾病的发生发展中起着重要的免疫调节作用。目前,IL-35已成为细胞因子研究的热点,为自身免疫性疾病、炎症性疾病等疾病的生物治疗提供了新方向。本文拟从IL-35的结构、生物学功能及其在口腔疾病中的研究进展作简要的综述。

关键词: 白细胞介素-35, 调节性T细胞, 免疫抑制

Abstract:

Interleukin (IL)-35 is a novel inhibitory cytokine produced by regulatory T (Treg) cells, which is the newest member of the IL-12 family of heterodimeric cytokines and offers the potential to be a target for new therapies for autoimmune, inflammatory, and infectious diseases. Unlike its proinflammatory relatives, IL-35 can contribute to the induction of new regulatory T and B cell populations and induce anti-inflammatory effects through inhibition of both T helper type 1 (Th1) and Th17 cells responses. IL-35 is likely to become a new cytokine research hotspot, for its role in oral diseases.

Key words: interleukin-35, regulatory T cell, immunosuppression

中图分类号: 

  • R781.5
[1] Pflanz S, Timans JC, Cheung J , et al. IL-27, a hetero-dimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 + T cells [J]. Im-munity, 2002,16(6):779-790.
doi: 10.1016/S1074-7613(02)00324-2 pmid: 12121660
[2] Niedbala W, Wei XQ, Cai B , et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells[J]. Eur J Immu- nol, 2007,37(11):3021-3029.
doi: 10.1002/eji.200737810 pmid: 17874423
[3] Collison LW, Workman CJ, Kuo TT , et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007,450(7169):566-569.
doi: 10.1038/nature06306 pmid: 18033300
[4] Collison LW, Vignali DA . Interleukin-35: odd one out or part of the family[J]. Immunol Rev, 2008,226:248-262.
doi: 10.1111/j.1600-065X.2008.00704.x pmid: 2631363
[5] Jones LL, Vignali DA . Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily[J]. Immunol Res, 2011,51(1):5-14.
doi: 10.1007/s12026-011-8209-y pmid: 3529148
[6] Oppmann B, Lesley R, Blom B , et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12[J]. Immunity, 2000,13(5):715-725.
doi: 10.1016/S1074-7613(00)00070-4
[7] Devergne O, Hummel M, Koeppen H , et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes[J]. J Virol, 1996,70(2):1143-1153.
doi: 10.1016/0166-0934(95)01969-3 pmid: 8551575
[8] Hibbert L, Pflanz S , De Waal Malefyt R, et al. IL-27 and IFN-α signal via Stat1 and Stat3 and induce T-Bet and IL-12Rβ2 in naive T cells[J]. J Interferon Cytokine Res, 2003,23(9):513-522.
doi: 10.1089/10799900360708632
[9] Bardel E, Larousserie F, Charlot-Rabiega P , et al. Human CD4 + CD25 + Foxp3 + regulatory T cells do not constitutively express IL-35 [J]. J Immunol, 2008,181(10):6898-6905.
doi: 10.4049/jimmunol.181.10.6898 pmid: 18981109
[10] Seyerl M, Kirchberger S, Majdic O , et al. Human rhinoviruses induce IL-35-producing Treg via induc-tion of B7-H1 (CD274) and sialoadhesin (CD169) on DC[J]. Eur J Immunol, 2010,40(2):321-329.
doi: 10.1002/eji.v40:2
[11] Li X, Mai J, Virtue A , et al. IL-35 is a novel respon-sive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines[J]. PLoS One, 2012,7(3):e33628.
doi: 10.1371/journal.pone.0033628
[12] Filková M, Vernerová Z, Hulejová H , et al. Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis[J]. Cytokine, 2015,73(1):36-43.
doi: 10.1016/j.cyto.2015.01.019 pmid: 25697137
[13] Long J, Zhang X, Wen M , et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells[J]. Biochem Biophys Res Commun, 2013,430(1):364-369.
doi: 10.1016/j.bbrc.2012.11.004 pmid: 23154182
[14] Presky DH, Yang H, Minetti LJ , et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits[J]. Proc Natl Acad Sci U S A, 1996,93(24):14002-14007.
doi: 10.1073/pnas.93.24.14002
[15] Chua AO, Wilkinson VL, Presky DH , et al. Cloning and characterization of a mouse IL-12 receptor-beta component[J]. J Immunol, 1995,155(9):4286-4294.
doi: 10.1089/jir.2007.0135 pmid: 7594587
[16] Collison LW, Delgoffe GM, Guy CS , et al. The composition and signaling of the IL-35 receptor are unconventional[J]. Nat Immunol, 2012,13(3):290-299.
doi: 10.1038/ni.2227 pmid: 3529151
[17] Wang RX, Yu CR, Dambuza IM , et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease[J]. Nat Med, 2014,20(6):633-641.
doi: 10.1038/nm.3554 pmid: 24743305
[18] Saito M, Yoshida K, Hibi M , et al. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo[J]. J Im-munol, 1992,148(12):4066-4071.
pmid: 1602143
[19] Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity[J]. Nat Rev Immunol, 2003,3(2):133-146.
doi: 10.1038/nri1001 pmid: 12563297
[20] Chen Q, Ghilardi N, Wang H , et al. Development of Th1-type immune responses requires the type Ⅰ cy- tokine receptor TCCR[J]. Nature, 2000,407(6806):916-920.
[21] Kochetkova I, Golden S, Holderness K , et al. IL-35 stimulation of CD39 + regulatory T cells confers pro-tection against collagen Ⅱ-induced arthritis via the production of IL-10 [J]. J Immunol, 2010,184(12):7144-7153.
doi: 10.4049/jimmunol.0902739
[22] Collison LW, Chaturvedi V, Henderson AL , et al. IL-35-mediated induction of a potent regulatory T cell population[J]. Nat Immunol, 2010,11(12):1093-1101.
doi: 10.1038/ni.1952 pmid: 20953201
[23] Liu JQ, Liu Z, Zhang X , et al. Increased Th17 and regulatory T cell responses in EBV-induced gene 3- deficient mice lead to marginally enhanced develop- ment of autoimmune encephalomyelitis[J]. J Immunol, 2012,188(7):3099-3106.
doi: 10.4049/jimmunol.1100106 pmid: 22387555
[24] Wirtz S, Billmeier U, Mchedlidze T , et al. Interleu-kin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis[J]. Gastroen-terology, 2011,141(5):1875-1886.
doi: 10.1053/j.gastro.2011.07.040 pmid: 3624892
[25] Bettini M, Castellaw AH, Lennon GP , et al. Preven-tion of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35[J]. Diabetes, 2012,61(6):1519-1526.
doi: 10.2337/db11-0784
[26] 施沛青, 朱书, 钱友存 . IL-17的信号传导及功能研究[J]. 中国细胞生物学学报, 2011,33(4):345-357.
Shi PQ, Zhu S, Qian YC . IL-17 signaling and func-tion[J]. Chin J Cell Biol, 2011,33(4):345-357.
[27] Yang J, Yang M, Htut TM , et al. Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORγt[J]. Eur J Immunol, 2008,38(5):1204-1214.
doi: 10.1002/(ISSN)1521-4141
[28] Huang CH, Loo EX, Kuo IC , et al. Airway inflam-mation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35[J]. J Immunol, 2011,187(1):462-471.
doi: 10.4049/jimmunol.1100259 pmid: 21613618
[29] Yoshizaki A, Miyagaki T , DiLillo DJ, et al. Regula-tory B cells control T-cell autoimmunity through IL- 21-dependent cognate interactions[J]. Nature, 2012,491(7423):264-268.
doi: 10.1038/nature11501
[30] Tirotta E, Duncker P, Oak J , et al. Epstein-Barr virus-induced gene 3 negatively regulates neuroinflamma-tion and T cell activation following coronavirus-induced encephalomyelitis[J]. J Neuroimmunol, 2013,254(1/2):110-116.
doi: 10.1016/j.jneuroim.2012.10.005
[31] 李姝文, 王秀敏, 李玉娟 . 寻常性银屑病患者外周血白介素27、白介素35及EBI3 mRNA表达的研究[J]. 中华皮肤科杂志, 2013,46(3):164-167.
doi: 10.3760/cma.j.issn.0412-4030.2013.03.005
Li SW, Wang XM, Li YJ . Expressions of interleu-kin-27, -35 and Epstein-Barr virus-induced gene 3 mRNA in peripheral blood of patients with psoriasis vulgaris[J]. Chin J Dermatol, 2013,46(3):164-167.
doi: 10.3760/cma.j.issn.0412-4030.2013.03.005
[32] Jafarzadeh A, Jamali M, Mahdavi R , et al. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program[J]. J Mol Neu-rosci, 2015,55(4):891-897.
doi: 10.1007/s12031-014-0443-z pmid: 25326790
[33] Ouyang H, Shi YB, Liu ZC , et al. Decreased inter-leukin 35 and CD4 +EBI3 + T cells in patients with active systemic lupus erythematosus [J]. Am J Med Sci, 2014,348(2):156-161.
doi: 10.1097/MAJ.0000000000000215 pmid: 25054737
[34] Yu W, Ge M, Lu S , et al. Anti-inflammatory effects of interleukin-35 in acquired aplastic anemia[J]. Cytokine, 2015,76(2):409-416.
doi: 10.1016/j.cyto.2015.08.004 pmid: 26282938
[35] Wang W, Li P, Chen YF , et al. A potential immuno-pathogenic role for reduced IL-35 expression in allergic asthma[J]. J Asthma, 2015,52(8):763-771.
doi: 10.3109/02770903.2015.1038390 pmid: 26044961
[36] Houshmandi N, Najafipour H, Joukar S , et al. The effect of interleukins 27 and 35 and their role on mediating the action of insulin like growth factor-1 on the inflammation and blood flow of chronically inflamed rat knee joint[J]. Cytokine, 2016,81:117-126.
doi: 10.1016/j.cyto.2016.03.010 pmid: 26994309
[37] Šenolt L, Šumová B, Jandová R , et al. Interleukin 35 synovial fluid levels are associated with disease ac-tivity of rheumatoid arthritis[J]. PLoS One, 2015,10(7):e0132674.
doi: 10.1371/journal.pone.0132674 pmid: 4512689
[38] Walton LJ, Macey MG, Thornhill MH , et al. Intra-epithelial subpopulations of T lymphocytes and Langerhans cells in oral lichen planus[J]. J Oral Pathol Med, 1998,27(3):116-123.
doi: 10.1111/j.1600-0714.1998.tb01926.x pmid: 9563803
[39] Piccinni MP, Lombardelli L, Logiodice F , et al. Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus[J]. Oral Dis, 2014,20(2):212-218.
doi: 10.1111/odi.12094 pmid: 23556506
[40] 刘芳 . 口腔扁平苔藓中Th17/Treg平衡与IL-35的相关性研究[D]. 贵阳: 贵州医科大学, 2016.
Liu F . Relativity analysis of Th17/Treg balance and IL-35 in oral lichen planus patients[D]. Guiyang: Guizhou Medical University, 2016.
[41] 黄韵颖 . IL-35对口腔扁平苔藓患者外周血Th17/Treg平衡的影响[D]. 贵阳: 贵州医科大学, 2017.
Huang YY . Effects of IL-35 on Th17/Treg balance in peripheral blood of patients with oral lichen planus[D]. Guiyang: Guizhou Medical University, 2017.
[42] Mitani A, Niedbala W, Fujimura T , et al. Increased expression of interleukin (IL)-35 and IL-17, but not IL-27, in gingival tissues with chronic periodontitis[J]. J Periodontol, 2015,86(2):301-309.
doi: 10.1902/jop.2014.140293
[43] Köseoğlu S, Sağlam M, Pekbağrıyanık T , et al. Level of Interleukin-35 in gingival crevicular fluid, saliva, and plasma in periodontal disease and health[J]. J Periodontol, 2015,86(8):964-971.
doi: 10.1902/jop.2015.140666 pmid: 2578656435
[44] 刘迪昕, 靳赢, 林晓萍 . IL-35在慢性牙周炎血清及龈沟液中的表达及相关性[J]. 上海口腔医学, 2015,24(4):455-459.
Liu DX, Jin Y, Lin XP . Expression and correlation of IL-35 in gingival crevicular fluid and serum with chronic periodontitis[J]. Shanghai J Stomatol, 2015,24(4):455-459.
[45] 麻婷婷, 王丽, 贾树芳 , 等. 牙周炎患者基础治疗前后龈沟液中IL-35浓度变化的研究[J]. 牙体牙髓牙周病学杂志, 2016,26(10):617-619.
doi: 10.15956/j.cnki.chin.j.conserv.dent.2016.10.008
Ma TT, Wang L, Jia SF , et al. Changes of IL-35 levels in giyngival crevicular fluid before and after basic periodontal treatment in periodontitis patients[J]. Chin J Conserv Dent, 2016,26(10):617-619.
doi: 10.15956/j.cnki.chin.j.conserv.dent.2016.10.008
[46] Wang HH, Liu CW, Li YC , et al. Efficacy of rituxi-mab for pemphigus: a systematic review and meta-analysis of different regimens[J]. Acta Derm Vene-reol, 2015,95(8):928-932.
doi: 10.2340/00015555-2116 pmid: 25881672
[47] Satyam A, Khandpur S, Sharma VK , et al. Involve-ment of TH1/TH2 cytokines in the pathogenesis of autoimmune skin disease—Pemphigus vulgaris[J]. Immunol Invest, 2009,38(6):498-509.
doi: 10.1080/08820130902943097
[48] Veldman C, Stauber A, Wassmuth R , et al. Dichotomy of autoreactive Th1 and Th2 cell responses to des-moglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class Ⅱalleles[J]. J Immunol, 2003,170(1):635-642.
doi: 10.4049/jimmunol.170.1.635 pmid: 12496453
[49] Xu RC, Zhu HQ, Li WP , et al. The imbalance of Th17 and regulatory T cells in pemphigus patients[J]. Eur J Dermatol, 2013,23(6):795-802.
doi: 10.1684/ejd.2013.2177 pmid: 24192290
[50] Tavakolpour S, Kheiry F, Mirsafaei HS , et al. The possible role of interleukin-35 and its therapeutic potential in pemphigus[J]. Int Immunopharmacol, 2017,42:11-17.
doi: 10.1016/j.intimp.2016.11.005 pmid: 27855302
[1] 姚懿桓, 王冏珂, 赵奎, 时玉洁, 曾昕, 陈谦明. 天疱疮的免疫抑制剂治疗方法[J]. 国际口腔医学杂志, 2018, 45(2): 155-161.
[2] 陈方曼,宗弋,李宇. 肾移植患者常见的口腔疾病[J]. 国际口腔医学杂志, 2015, 42(5): 611-614.
[3] 李欣综述 李龙江审校. 环境因素在非霍奇金淋巴瘤病因中作用的研究进展[J]. 国际口腔医学杂志, 2009, 36(3): 323-325.
[4] 连晓妹,林李嵩,陈乃俊,. 颜面复合组织同种异体移植研究进展[J]. 国际口腔医学杂志, 2007, 34(04): 293-295.
[5] 王斯华综述 唐休发审校. 肿瘤原发灶的治疗促进肿瘤转移的相关机制[J]. 国际口腔医学杂志, 2006, 33(04): 323-325.
[6] 叶冬霞. 头颈鳞癌CD34~+细胞免疫抑制作用的研究进展[J]. 国际口腔医学杂志, 2002, 29(04): -.
[7] 耿海霞. 疱疹病毒感染与口腔溃疡[J]. 国际口腔医学杂志, 1999, 26(04): -.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 汤庆奋,王学侠. 17β-雌二醇对人类阴道和口腔颊粘膜的渗透性[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 潘劲松. 颈总动脉指压和颈内动脉球囊阻断试验在大脑血液动力学中的不同影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[3] 王昆润. 后牙冠根斜形牙折的治疗[J]. 国际口腔医学杂志, 1999, 26(05): .
[4] 杨锦波. 嵌合体防龋疫苗的研究进展[J]. 国际口腔医学杂志, 1999, 26(05): .
[5] 王昆润. 下颔骨成形术用网状钛板固定植骨块[J]. 国际口腔医学杂志, 1999, 26(04): .
[6] 汪月月,郭莉莉. 口腔机能与老化—痴呆危险因素流行病学研究[J]. 国际口腔医学杂志, 1999, 26(04): .
[7] 丁刚. 应用硬组织代用品种植体行丰颏术[J]. 国际口腔医学杂志, 1999, 26(04): .
[8] 戴青. 口腔念珠菌病的新分类[J]. 国际口腔医学杂志, 1999, 26(04): .
[9] 王金涛 刘美娟 孙宏晨 欧阳喈. 牙槽嵴牵张成骨[J]. 国际口腔医学杂志, 2004, 31(02): 146 -148 .
[10] 蔡霞,李成章. 前列腺素E_2受体EP亚型在牙周炎发病机制中的作用[J]. 国际口腔医学杂志, 2005, 32(06): 461 -462 .